Sun R, Ning Z, Qin H, Zhang W, Teng Y, Jin C
Sci Rep. 2024; 14(1):9552.
PMID: 38664423
PMC: 11045761.
DOI: 10.1038/s41598-024-55829-5.
Jain A, Gesiotto Q, Ball S, Nodzon L, Rodriguez A, Chan O
Ann Hematol. 2024; 103(6):1941-1945.
PMID: 38634915
PMC: 11090947.
DOI: 10.1007/s00277-024-05760-6.
Kucukyurt S, Eskazan T, Ayer M, Kilickiran Avci B, Hatemi I, Eskazan A
Pleura Peritoneum. 2024; 9(1):39-43.
PMID: 38558869
PMC: 10980979.
DOI: 10.1515/pp-2023-0016.
Rosti G, Brummendorf T, Gjertsen B, Giraldo-Castellano P, Castagnetti F, Gambacorti-Passerini C
Leukemia. 2023; 38(1):126-135.
PMID: 38007586
PMC: 10776383.
DOI: 10.1038/s41375-023-02080-y.
Kwok C, Nolan M
Front Cardiovasc Med. 2023; 10:1150569.
PMID: 37745115
PMC: 10516301.
DOI: 10.3389/fcvm.2023.1150569.
Dasatinib-Induced Chylothorax Beyond 5 Years of Treatment: Is There Actually Any Limit?.
Garcia-Zamalloa A, Basauri B, Urcelay G, Sainz A
Eur J Case Rep Intern Med. 2023; 10(7):003921.
PMID: 37455693
PMC: 10348434.
DOI: 10.12890/2023_003921.
Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies.
Cheng F, Xu Q, Li Q, Cui Z, Li W, Zeng F
Front Oncol. 2023; 13:1113462.
PMID: 36814818
PMC: 9939513.
DOI: 10.3389/fonc.2023.1113462.
Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia.
Harrington P, Dillon R, Radia D, Rousselot P, McLornan D, Ong M
Haematologica. 2023; 108(6):1555-1566.
PMID: 36700403
PMC: 10230408.
DOI: 10.3324/haematol.2022.282005.
Exacerbation of pleural effusion in a dasatinib-treated patient during the perioperative period.
Hasegawa T, Inoue S, Yoshida K, Akatsu M
JA Clin Rep. 2022; 8(1):87.
PMID: 36279015
PMC: 9590538.
DOI: 10.1186/s40981-022-00577-6.
Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia.
Yoshifuji K, Sasaki K
Front Oncol. 2022; 12:1021662.
PMID: 36276124
PMC: 9583346.
DOI: 10.3389/fonc.2022.1021662.
Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event.
Pasquale R, Bucelli C, Bellani V, Zappa M, Iurlo A, Cattaneo D
Front Oncol. 2022; 12:1012268.
PMID: 36176390
PMC: 9513037.
DOI: 10.3389/fonc.2022.1012268.
Dasatinib-induced chylothorax: An unusual presentation of a common adverse event-A case report with literature review.
Paul T, Ellahie A, Almohtasib Y, Sinha U, El Omri H
EJHaem. 2022; 2(3):545-550.
PMID: 35844702
PMC: 9175909.
DOI: 10.1002/jha2.226.
A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase.
Garcia-Gutierrez V, Breccia M, Jabbour E, Mauro M, Cortes J
J Hematol Oncol. 2022; 15(1):90.
PMID: 35818053
PMC: 9272596.
DOI: 10.1186/s13045-022-01309-0.
Pericardial Effusion Secondary to Nilotinib in an Elderly Patient With Chronic Myelogenous Leukemia.
Arora G, Adinugraha P, Aijaz A, Vargas Pelaez A, Rachko M
Cureus. 2022; 14(4):e23855.
PMID: 35530911
PMC: 9072281.
DOI: 10.7759/cureus.23855.
Comparison of Dasatinib- and Imatinib-Related Cardiotoxic Adverse Events in Japanese Patients With Chronic Myeloid Leukemia and Gastrointestinal Stromal Tumor.
Motokawa T, Ikeda S, Ueno Y, Eguchi M, Minami T, Kawano H
Circ Rep. 2022; 4(1):1-8.
PMID: 35083382
PMC: 8710638.
DOI: 10.1253/circrep.CR-21-0140.
Dasatinib-Induced Pleural and Pericardial Effusions.
Hailan Y, Elyas A, Abdulla M, Yassin M
Cureus. 2021; 13(10):e19024.
PMID: 34824936
PMC: 8611763.
DOI: 10.7759/cureus.19024.
Management of Adverse Events Associated With Tyrosine Kinase Inhibitor Use in Adult Patients With Chronic Myeloid Leukemia in Chronic Phase: An Advanced Practice Perspective.
Bauer S, Comer H, Ramsey B, Thomas K
J Adv Pract Oncol. 2021; 12(5):521-533.
PMID: 34430062
PMC: 8299797.
DOI: 10.6004/jadpro.2021.12.5.7.
Pleural Effusion Secondary to Dasatinib Following Allogenic Hematopoietic Stem Cell Transplantation.
Alrubaye R, Fadel C, Adewunmi C, Del Rio Lopez L
Am J Case Rep. 2021; 22:e932711.
PMID: 34362863
PMC: 8363658.
DOI: 10.12659/AJCR.932711.
Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review.
Santoro M, Mancuso S, Accurso V, Di Lisi D, Novo G, Siragusa S
Front Physiol. 2021; 12:675811.
PMID: 34290617
PMC: 8287514.
DOI: 10.3389/fphys.2021.675811.
[Dasatinib-related pulmonary adverse events in patients with chronic myeloid leukemia].
Yang S, Qin Y, Lai Y, Shi H, Hou Y, Huang X
Zhonghua Xue Ye Xue Za Zhi. 2021; 41(12):1013-1019.
PMID: 33445849
PMC: 7840556.
DOI: 10.3760/cma.j.issn.0253-2727.2020.12.008.
